Item type |
琉球大学リポジトリ登録用アイテムタイプ(1) |
公開日 |
2023-01-27 |
タイトル |
|
|
タイトル |
Changes in Pharmacodynamic Parameters during Co-administration of 5-FU with Warfarin: A Retrospective Case Series |
|
言語 |
en |
作成者 |
Tayag, Jose Carlos S.
Ishii, Takeo
Kokuba, Shun
Hirata, Tetsuo
Shiohira, Hideo
Nakamura, Katsunori
|
アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
権利情報 |
|
|
言語 |
en |
|
権利情報 |
© 2022 The Pharmaceutical Society of Japan |
主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
5-fluorouracil |
主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
warfarin |
主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
fluoropyrimidine |
主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
CYP |
主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
drug interaction |
主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
chemotherapy |
内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Drug–drug interactions (DDIs) between warfarin (WF) and fluoropyrimidines are well known. Co-administration of WF and 5-fluorouracil (5-FU) leads to elevations in prothrombin time international normalised ratio (PT-INR). The inhibition of drug metabolism through suppression of CYP activity is a possible cause of prolonged PT-INR elevations. 5-FU and its metabolites are suspected to inhibit CYPs, but the precise mechanisms of action remain unknown. This study aimed to investigate the possible DDI effects of the co-administration of 5-FU with WF using PT-INR and PT-INR/dose ratio as pharmacodynamic parameters. Retrospective case series data were collected from patients who received parenteral 5-FU chemotherapy from April 2009 to December 2019 at the University of the Ryukyus Hospital. Seven patients who received 5-FU in combination with WF were analysed. There was a significant increase in PT-INR and PT-INR/dose during the co-administration of WF and 5-FU (p= 0.0018 and p= 0.0187, respectively; paired t-test). The findings demonstrated significant DDI between 5-FU and WF evident as elevated PT-INR and PT-INR/dose ratio. |
|
言語 |
en |
出版者 |
|
|
言語 |
en |
|
出版者 |
The Pharmaceutical Society of Japan |
言語 |
|
|
言語 |
eng |
資源タイプ |
|
|
資源タイプ |
journal article |
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1248/bpb.b22-00129 |
収録物識別子 |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
1347-5215 |
収録物識別子 |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0918-6158 |
収録物名 |
|
|
言語 |
en |
|
収録物名 |
Biological and Pharmaceutical Bulletin |
書誌情報 |
巻 45,
号 8,
p. 1101-1105,
発行日 2022
|